Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus temozolomide versus temozolomide alone after radiotherapy in children and young adults with newly diagnosed high-grade glioma
2022-502269-13-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial in glioma comparing Abemaciclib plus temozolomide with Temozolomide monotherapy (2 arms). Primary endpoint: Event-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
abemaciclibtemozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on 2022-502269-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502269-13-00.